All Posts

These medications could be one reason why weight room floors seem busier than ever.

(MedPage Today) — People with pre-existing depression or anxiety were less likely to have mental health worsening while taking a GLP-1 medication, observational Swedish data suggested.
Compared with periods of non-use in the same individual…

So you’ve decided to go on a GLP-1 to lose weight. These medicines might seem like an easy way to drop unwanted pounds, but you’ll likely need to do a few other things to be successful long-term.

A new type of daily pill has proven more effective for weight loss and blood sugar control than its currently available counterparts, according to a recent trial. The drug, known as orforglipron, could be a game-changer in the rapidly expanding oral weight-loss drug market.

In new research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May), a global panel of 21 obesity and cancer experts suggest that to test the potential efficacy of the new generation of obesity drugs such as semaglutide and tirzepatide in preventing obesity-related cancer (ORC), a trial of the drugs for some 5,000 participants at high risk of cancer due to their having a cancer pre-cursor condition will provide the required answers.

WEDNESDAY, March 25, 2026 — Glucagon-like peptide-1 (GLP-1) receptor agonists, especially semaglutide, are associated with a reduced risk for worsening of anxiety and depression that co-occur with diabetes and obesity, according to a study…

The FDA has approved a higher dose of Wegovy, which promises greater weight loss. Image Credit: Bloomberg/Getty Images

The FDA has approved a higher dose version of the GLP-1 drug Wegovy for weight loss. 

The new dose is 7.2 milligrams per weekly injection, compared to the original 2.4 milligrams per week. 

This year’s catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo Nordisk is expecting more clinical data for next-gen weight loss asset CagriSema, which recently lost a head-to-head battle with Lilly’s Zepbound.

Eli Lilly and the “societal obligation” of GLP-1s, Merck’s Terns Pharma purchase, and more biotech news in today’s Readout newsletter.

Fourteen years ago, a group of Harvard Business School students launched a startup called Vaxess Technologies with a goal to disrupt the vaccine industry by replacing needles with a simple skin patch.
Getting the technology …

Kendra Wilkinson says she plans to start GLP-1 weight-loss shots after turning 40, noting her jeans feel tighter but insisting she is happy and at peace.

The FDA approved Wegovy HD, a higher-dose semaglutide for weight loss in adults with obesity, offering greater weight reduction, as experts warn of side effects.

Stopping GLP-1 drugs like Ozempic quickly erodes heart protection, with two years off the medication raising cardiovascular risk by 22%, a new study finds.

New research suggests that GLP-1s could offer dual benefits for treating both metabolic and mental health issues. Catherine Falls Commercial/Getty Images

A new study found that people taking GLP-1 drugs like Ozempic and Wegovy had a lower risk of worsening depression and anxiety.

The participants also had fewer hospitalizations and required less sick leave from their jobs.

Experts say the drugs’ effects on dopamine signaling and brain inflammation could account for the benefits.

It’s too soon to recommend GLP-1s as a primary treatment for mental health disorders. Further clinical trials are still needed.

MONDAY, March 23, 2026 — Periconceptional exposure to glucagon-like peptide-1 (GLP-1) receptor agonists is associated with increased odds of preterm birth among women with diabetes, according to a study published online March 18 in Human…

Whether they’re using weekly shots or daily pills, more Americans than ever are turning to anti-obesity drugs to lose weight and boost health.

A stronger version of the popular weight loss drug Wegovy is on the way after federal regulators signed off on a higher dose. The U.S. Food and Drug Administration (FDA) approved a 7.2-milligram dose of Novo Nordisk’s semaglutide, the active ingredient in Wegovy. Until now, the highest approved dose was 2.4 milligrams, taken as a weekly shot.

Big food companies are starting to market to people on the powerful new obesity meds with labels that say “GLP-1 Friendly.” Nutritionists help us decode that message.

Weight-loss injections that have become famous for helping people shed pounds may also help some patients with advanced cancer live longer when the disease has spread to the brain, according to a new study.

GLP-1 medications like semaglutide (Ozempic) may offer unexpected mental health benefits alongside weight loss. A large study found major drops in depression, anxiety, and psychiatric-related hospital visits among users. Even substance use disorders were significantly lower during treatment. Researchers suspect both lifestyle improvements and direct brain effects could be at play.

Protein products are flooding grocery shelves as influencers promote high-protein diets, but nutrition experts caution the anti-carb trend oversimplifies eating.

Welcome to another edition of Endpoints Weekly — and happy spring! The weather may not feel very spring-like here in NYC (outside that false start a couple weeks ago), but we’re grateful the sidewalk snowbanks are …

Stopping GLP-1s can quickly reverse the cardiovascular benefits gained while taking them. Image Credit: the_burtons/Getty Images

A recent study found that stopping GLP-1s, such as Ozempic or Wegovy, can reverse the cardiovascular benefits they provide. 

The findings show that stopping the medications for as little as 6 months raises the risk of heart attack and stroke. 

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer’s disease, finds the first large Phase III randomized controlled trials on the topic published in The Lancet.

FRIDAY, March 20, 2026 — Drugs like Ozempic and Mounjaro are known to lower the risk of heart attack and stroke, but a new study suggests those benefits may not last if people stop taking them.Researchers found that heart risks begin to rise again w…

And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…

Stopping popular weight-loss injections like Ozempic or Mounjaro might not trigger the dramatic rebound many fear. A large real-world study of nearly 8,000 patients found that most people who discontinue these drugs manage to keep the weight off—or even continue losing—by restarting treatment, switching medications, or adopting lifestyle changes. While earlier clinical trials suggested rapid weight regain, this new evidence paints a more hopeful picture.

(MedPage Today) — The FDA approved a higher dose of the GLP-1 receptor agonist semaglutide for weight loss, dubbed Wegovy HD, the agency announced on Thursday.
The once-weekly injectable will come in a 7.2-mg dose — three times the strength…

INDIANAPOLIS, March 19, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational…

With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.

The FDA approved a high-dose version of Novo Nordisk’s blockbuster weight loss injection Wegovy, giving its go-ahead about two months faster than normal thanks to a voucher received from the commissioner’s program.

Thursday’s approval is …

A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval.

In a sea of uncertainty, a large-scale, long-term Swedish study is the first to show that people using GLP-1 receptor agonists are less likely to have worsening mental illness. The study involved a national cohort of 95,490 people diagnosed with depression or anxiety disorder, who also were treated with any diabetes drug (apart from insulin).

Further weight loss details are yet to come this year, but Eli Lilly and Co. scored positive top-line results in Transcend-T2D-1, a phase III trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise in type 2 diabetes (T2D).

Eli Lilly’s so-called triple-G reduced blood sugar levels in patients with type 2 diabetes by up to 1.9% in a late-stage trial — a slightly lower margin than Mounjaro achieved in its pivotal diabetes study.

The …

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.

Drugs such as semaglutide may be useful for mental health conditions associated with diabetes, authors sayDiabetes drugs could prevent anxiety and depression from worsening, according to research.Type 2 diabetes affects more than 800 million people globally and research shows that those with the condition are about twice as likely to have depression as the wider population. Continue reading…

GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a new study shows. The large register-based study was carried out in collaboration between the University of Eastern Finland, Karolinska Institutet in Stockholm and Griffith University in Australia.

The study findings may spark treatment innovations for depression and anxiety.